Adaptive Biotechnologies' clonoSEQ MRD test can be used to guide post-transplant treatment decisions in multiple myeloma patients

Adaptive Biotechnologies and its collaborators have presented data at the American Society of Hematology (ASH) Annual Meeting showing that the clonoSEQ® minimal residual disease (MRD) Test can… Source link